Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma
The improvement in outcomes seen with the introduction of rituximab, a CD20 monoclonal antibody in combination with chemotherapy or as a single agent in the treatment of indolent non-Hodgkin lymphomas has paved the way for development of various forms of monoclonal antibodies that act in different w...
Main Authors: | Suheil Albert Atallah-Yunes, Michael J. Robertson |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-01-01
|
Series: | Leukemia Research Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048922000310 |
Similar Items
-
Bispecific antibodies and their use in applied research
by: Harshit Verma, et al.
Published: (2012-01-01) -
Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
by: Waqqas Tai, et al.
Published: (2022-03-01) -
Role of antibody-based therapy in indolent non-Hodgkin's lymphoma
by: Patrick Willard, et al.
Published: (2021-01-01) -
Bispecific antibodies: design, therapy, perspectives
by: Sedykh SE, et al.
Published: (2018-01-01) -
Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
by: Mattia D’Agostino, et al.
Published: (2020-11-01)